Black Diamond Therapeutics Inc (BDTX NASDAQ) stock market data APIs
$2.2107
0.07(3.2%)
as of August 28, 2026
Try our APIs with
free plan!
Black Diamond Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Prev. Close
2.2107
Open
2.2839
High
2.2922
Low
2.1874
52 wk Range
1.6-4.94
Market Cap
128 M
Shares Outstanding
57 454 K
EPS
-0.17
Beta
3.288
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Black Diamond Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Black Diamond Therapeutics Inc data using free add-ons & libraries
Get Black Diamond Therapeutics Inc Fundamental Data
Black Diamond Therapeutics Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -44 349 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Black Diamond Therapeutics Inc Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2026-08-05
- EPS/Forecast: -0.18
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Black Diamond Therapeutics Inc News
New
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
Black Diamond Therapeutics BDTX is widening the opportunity set for silevertinib by pushing beyond lung cancer and into glioblastoma, a move that leans on the same core attribute that has driven inves...
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
Black Diamond Therapeutics BDTX delivered a modest first-quarter earnings beat, but the stock’s story remains almost entirely clinical. Investors are underwriting one main question: can silevertinib...
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
Black Diamond Therapeutics BDTX is building its equity story around one drug, silevertinib, a brain-penetrant, fourth-generation EGFR inhibitor being studied in EGFR–mutant non-small cell lung cance...
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
Black Diamond Therapeutics BDTX shares fell 35.8% as investors appeared to take a mixed view of the latest phase II update for the company’s lead candidate, silevertinib, being evaluated for first-l...
Get Black Diamond Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
